What question did this study set out to answer?

To evaluate the effects of tirzepatide on glomerular hyperfiltration and eGFR in youth-onset type 2 diabetes.

June 7, 2026

1134-OR: Reduction in Glomerular Hyperfiltration with Tirzepatide in Youth-Onset T2D

Key Points

To evaluate the effects of tirzepatide on glomerular hyperfiltration and eGFR in youth-onset type 2 diabetes.
Randomized controlled trial comparing tirzepatide (5 mg and 10 mg) with placebo for 30 weeks.
Participants aged 10 to <18 years with youth-onset type 2 diabetes on metformin and/or basal insulin were included.
Hyperfiltration defined as eGFR ≥126.8 mL/min/1.73 m², assessed using Zappitelli equation.
Mean eGFR decreased in tirzepatide-treated participants, particularly those with baseline hyperfiltration.
Proportion of participants with hyperfiltration decreased from 18.6% to 5.5% in pooled tirzepatide group, while increasing in placebo from 16.1% to 21.9% (p<0.05).
Overall mean reduction in eGFR was mainly attributed to decreased hyperfiltration.

Abstract

Introduction and Objective: Tirzepatide (TZP) demonstrated improvements in glycemic control and BMI in participants with youth-onset type 2 diabetes (YT2D) in SURPASS-PEDS. TZP impact on glomerular hyperfiltration, an early disease marker affecting 24% of YT2D, was not previously assessed. This analysis examined changes in estimated glomerular filtration rate (eGFR) and hyperfiltration status with TZP treatment. Methods: TZP vs PBO was assessed for 30 weeks in participants 10 to 18 years old with YT2D on metformin and/or basal insulin. Participants received TZP 5 mg (n=32), 10 mg (n=33) or PBO (n=34). eGFR was calculated using Zappitelli creatinine-cystatin C equation; hyperfiltration was defined as eGFR ≥126.8 mL/min/1.73 m². Change in eGFR (MMRM) and shifts in hyperfiltration status (Fisher’s exact test) were assessed. Results: At baseline, mean age was 14.7 years old and 18% of participants exhibited hyperfiltration (mean eGFR 142 vs 104 mL/min/1.73m2 in normofiltration). TZP treatment led to a reduction in eGFR at Week 30, with greater than two-times reduction in participants with baseline hyperfiltration (Table 1). The proportion of participants with hyperfiltration decreased in pooled TZP (18.6% to 5.5%) and increased in PBO (16.1% to 21.9%, p0.05, TZP vs PBO). Conclusion: In the SURPASS-PEDS trial, treatment with tirzepatide was associated with a mean decrease in eGFR, primarily ascribed to attenuation of glomerular hyperfiltration.Trial registration: ClinicalTrials.gov (NCT05260021). Disclosure P. Bjornstad: Consultant; Current; Bayer AG, Boehringer Ingelheim International GmbH, Lilly, Novo Nordisk. T.S. Hannon: None. J.M. Maldonado: Employee; Current; Eli Lilly and Company. K. Ranta: Employee; Current; Eli Lilly and Company. K. Pamidipati: None. H. Patel: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. B. Bergman: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. Funding Eli Lilly and Company

Bookmark

1134-OR: Reduction in Glomerular Hyperfiltration with Tirzepatide in Youth-Onset T2D

Key Points

Abstract

Cite This Study